GlucoTrack (GCTK) Competitors

GlucoTrack logo
$0.20 +0.01 (+4.21%)
As of 11/18/2026 02:54 PM Eastern

GCTK vs. BTCY, BBLG, NXL, DYNT, and BIOL

Should you buy GlucoTrack stock or one of its competitors? GlucoTrack's main competitors and comparable companies include Biotricity (BTCY), Bone Biologics (BBLG), Nexalin Technology (NXL), Dynatronics (DYNT), and BIOLASE (BIOL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does GlucoTrack compare to Biotricity?

GlucoTrack (NASDAQ:GCTK) and Biotricity (NASDAQ:BTCY) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, institutional ownership, valuation, earnings, risk, dividends, profitability and analyst recommendations.

10.9% of GlucoTrack shares are owned by institutional investors. Comparatively, 3.9% of Biotricity shares are owned by institutional investors. 5.9% of GlucoTrack shares are owned by company insiders. Comparatively, 1.6% of Biotricity shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

GlucoTrack has a net margin of 0.00% compared to Biotricity's net margin of -80.42%. Biotricity's return on equity of 0.00% beat GlucoTrack's return on equity.

Company Net Margins Return on Equity Return on Assets
GlucoTrackN/A -2,135.52% -290.22%
Biotricity -80.42%N/A -188.47%

Biotricity has higher revenue and earnings than GlucoTrack. Biotricity is trading at a lower price-to-earnings ratio than GlucoTrack, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GlucoTrackN/AN/A-$19.39M-$275.26N/A
Biotricity$12.06M0.09-$14.09M-$0.14N/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
GlucoTrack
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Biotricity
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

GlucoTrack has a beta of 0.9, meaning that its share price is 10% less volatile than the broader market. Comparatively, Biotricity has a beta of 1.03, meaning that its share price is 3% more volatile than the broader market.

In the previous week, GlucoTrack had 1 more articles in the media than Biotricity. MarketBeat recorded 1 mentions for GlucoTrack and 0 mentions for Biotricity. GlucoTrack's average media sentiment score of 0.00 equaled Biotricity'saverage media sentiment score.

Company Overall Sentiment
GlucoTrack Neutral
Biotricity Neutral

Summary

GlucoTrack and Biotricity tied by winning 6 of the 12 factors compared between the two stocks.

How does GlucoTrack compare to Bone Biologics?

GlucoTrack (NASDAQ:GCTK) and Bone Biologics (NASDAQ:BBLG) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, media sentiment, earnings, analyst recommendations and dividends.

In the previous week, GlucoTrack had 1 more articles in the media than Bone Biologics. MarketBeat recorded 1 mentions for GlucoTrack and 0 mentions for Bone Biologics. GlucoTrack's average media sentiment score of 0.00 equaled Bone Biologics'average media sentiment score.

Company Overall Sentiment
GlucoTrack Neutral
Bone Biologics Neutral

10.9% of GlucoTrack shares are held by institutional investors. Comparatively, 34.3% of Bone Biologics shares are held by institutional investors. 5.9% of GlucoTrack shares are held by company insiders. Comparatively, 5.0% of Bone Biologics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
GlucoTrack
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Bone Biologics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Bone Biologics' return on equity of -57.07% beat GlucoTrack's return on equity.

Company Net Margins Return on Equity Return on Assets
GlucoTrackN/A -2,135.52% -290.22%
Bone Biologics N/A -57.07%-52.54%

GlucoTrack has a beta of 0.9, meaning that its share price is 10% less volatile than the broader market. Comparatively, Bone Biologics has a beta of 0.91, meaning that its share price is 9% less volatile than the broader market.

Bone Biologics is trading at a lower price-to-earnings ratio than GlucoTrack, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GlucoTrackN/AN/A-$19.39M-$275.26N/A
Bone BiologicsN/AN/A-$3.11M-$1.17N/A

Summary

Bone Biologics beats GlucoTrack on 6 of the 8 factors compared between the two stocks.

How does GlucoTrack compare to Nexalin Technology?

Nexalin Technology (NASDAQ:NXL) and GlucoTrack (NASDAQ:GCTK) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, media sentiment, risk, valuation, profitability and analyst recommendations.

GlucoTrack has a net margin of 0.00% compared to Nexalin Technology's net margin of -3,384.12%. Nexalin Technology's return on equity of -445.53% beat GlucoTrack's return on equity.

Company Net Margins Return on Equity Return on Assets
Nexalin Technology-3,384.12% -445.53% -256.45%
GlucoTrack N/A -2,135.52%-290.22%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nexalin Technology
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50
GlucoTrack
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, Nexalin Technology had 1 more articles in the media than GlucoTrack. MarketBeat recorded 2 mentions for Nexalin Technology and 1 mentions for GlucoTrack. GlucoTrack's average media sentiment score of 0.00 beat Nexalin Technology's score of -1.01 indicating that GlucoTrack is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Nexalin Technology
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Negative
GlucoTrack
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

0.7% of Nexalin Technology shares are owned by institutional investors. Comparatively, 10.9% of GlucoTrack shares are owned by institutional investors. 17.1% of Nexalin Technology shares are owned by company insiders. Comparatively, 5.9% of GlucoTrack shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Nexalin Technology has higher revenue and earnings than GlucoTrack. Nexalin Technology is trading at a lower price-to-earnings ratio than GlucoTrack, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nexalin Technology$300K3.50-$8.22M-$13.94N/A
GlucoTrackN/AN/A-$19.39M-$275.26N/A

Nexalin Technology has a beta of 4.31, suggesting that its share price is 331% more volatile than the broader market. Comparatively, GlucoTrack has a beta of 0.9, suggesting that its share price is 10% less volatile than the broader market.

Summary

Nexalin Technology beats GlucoTrack on 9 of the 12 factors compared between the two stocks.

How does GlucoTrack compare to Dynatronics?

Dynatronics (NASDAQ:DYNT) and GlucoTrack (NASDAQ:GCTK) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, dividends, media sentiment, risk, valuation, profitability, analyst recommendations and institutional ownership.

Dynatronics has a beta of 0.31, indicating that its share price is 69% less volatile than the broader market. Comparatively, GlucoTrack has a beta of 0.9, indicating that its share price is 10% less volatile than the broader market.

4.2% of Dynatronics shares are owned by institutional investors. Comparatively, 10.9% of GlucoTrack shares are owned by institutional investors. 2.9% of Dynatronics shares are owned by insiders. Comparatively, 5.9% of GlucoTrack shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

GlucoTrack has a net margin of 0.00% compared to Dynatronics' net margin of -8.35%. Dynatronics' return on equity of -41.81% beat GlucoTrack's return on equity.

Company Net Margins Return on Equity Return on Assets
Dynatronics-8.35% -41.81% -9.56%
GlucoTrack N/A -2,135.52%-290.22%

Dynatronics has higher revenue and earnings than GlucoTrack. GlucoTrack is trading at a lower price-to-earnings ratio than Dynatronics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dynatronics$33.60M0.00-$2.70M-$1.35N/A
GlucoTrackN/AN/A-$19.39M-$275.26N/A

Given Dynatronics' higher possible upside, equities analysts clearly believe Dynatronics is more favorable than GlucoTrack.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Dynatronics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
GlucoTrack
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, GlucoTrack had 1 more articles in the media than Dynatronics. MarketBeat recorded 1 mentions for GlucoTrack and 0 mentions for Dynatronics. Dynatronics' average media sentiment score of 0.00 equaled GlucoTrack'saverage media sentiment score.

Company Overall Sentiment
Dynatronics Neutral
GlucoTrack Neutral

Summary

GlucoTrack beats Dynatronics on 7 of the 13 factors compared between the two stocks.

How does GlucoTrack compare to BIOLASE?

GlucoTrack (NASDAQ:GCTK) and BIOLASE (NASDAQ:BIOL) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, analyst recommendations, media sentiment and institutional ownership.

Given BIOLASE's higher probable upside, analysts clearly believe BIOLASE is more favorable than GlucoTrack.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
GlucoTrack
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
BIOLASE
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

GlucoTrack has higher earnings, but lower revenue than BIOLASE. GlucoTrack is trading at a lower price-to-earnings ratio than BIOLASE, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GlucoTrackN/AN/A-$19.39M-$275.26N/A
BIOLASE$48.83M0.00-$20.63M-$14.94N/A

10.9% of GlucoTrack shares are owned by institutional investors. Comparatively, 8.8% of BIOLASE shares are owned by institutional investors. 5.9% of GlucoTrack shares are owned by insiders. Comparatively, 0.3% of BIOLASE shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

GlucoTrack has a beta of 0.9, suggesting that its stock price is 10% less volatile than the broader market. Comparatively, BIOLASE has a beta of 0.67, suggesting that its stock price is 33% less volatile than the broader market.

GlucoTrack has a net margin of 0.00% compared to BIOLASE's net margin of -41.65%. BIOLASE's return on equity of -1,782.73% beat GlucoTrack's return on equity.

Company Net Margins Return on Equity Return on Assets
GlucoTrackN/A -2,135.52% -290.22%
BIOLASE -41.65%-1,782.73%-55.31%

In the previous week, GlucoTrack had 1 more articles in the media than BIOLASE. MarketBeat recorded 1 mentions for GlucoTrack and 0 mentions for BIOLASE. GlucoTrack's average media sentiment score of 0.00 equaled BIOLASE'saverage media sentiment score.

Company Overall Sentiment
GlucoTrack Neutral
BIOLASE Neutral

Summary

GlucoTrack beats BIOLASE on 7 of the 13 factors compared between the two stocks.

Get GlucoTrack News Delivered to You Automatically

Sign up to receive the latest news and ratings for GCTK and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GCTK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GCTK vs. The Competition

MetricGlucoTrackHealthcare Equipment & Supplies IndustryHealthcare SectorNASDAQ Exchange
Market Cap$234K$5.92B$7.72B$11.67B
Dividend YieldN/A1.69%2.47%4.56%
P/E Ratio0.0035.1732.3428.14
Price / SalesN/A4.998.355.64
Price / CashN/A23.3720.8521.62
Price / Book0.004.204.443.72
Net Income-$19.39M$143.14M$3.51B$394.03M
7 Day Performance-17.50%-3.62%-4.69%-4.67%
1 Month Performance-85.54%-4.18%-5.66%-7.21%
1 Year Performance-99.87%-0.09%-1.17%-7.05%

GlucoTrack Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GCTK
GlucoTrack
0.1665 of 5 stars
$0.20
+4.2%
N/A-99.9%$234KN/AN/A5
BTCY
Biotricity
N/A$0.06
flat
N/A-89.1%$1.20M$12.06MN/A46
BBLG
Bone Biologics
1.0252 of 5 stars
$0.35
+2.6%
N/A-82.1%$1.16MN/AN/A2
NXL
Nexalin Technology
0.5384 of 5 stars
$1.59
+8.2%
N/A-95.5%$1.08M$300KN/A8
DYNT
Dynatronics
N/AN/AN/AN/A$653K$33.60MN/A200

Related Companies and Tools


This page (NASDAQ:GCTK) was last updated on 11/19/2026 by MarketBeat.com Staff.
From Our Partners